Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | NQO2 | P16083 | 2/20 | 0.58 |
| ▸ | DDX3X | O00571 | 1/20 | 0.58 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | USP7 | Q93009 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374432 | 0.89 | ALDH1A1 (1.00) | ALDH1A1NQO2DDX3XCYP1A2HSD17B10 | |
| SCHEMBL29557251 | 0.89 | ALDH1A1 (1.00) | ALDH1A1NQO2DDX3XCYP1A2HSD17B10 | |
| SCHEMBL6796771 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAP4K4HSD17B10SMN1; SMN2CYP17A1 | |
| SCHEMBL4654909 | 0.88 | ALDH1A1 (0.67) | ALDH1A1NQO2MAP4K4HSD17B1HSD17B2 | |
| Hydrochloric Acid SCHEMBL2481626 | 0.87 | ALDH1A1 (0.96) | ALDH1A1NQO2DDX3XCYP1A2HSD17B10 | |
| SCHEMBL4189391 | 0.85 | PIP4K2A (0.62) | ALDH1A1NQO2MAP4K4FYNUSP7 | |
| SCHEMBL3786463 | 0.84 | NQO2 (0.73) | ALDH1A1NQO2HSD17B1HSD17B2CYP1A2 | |
| Formic Acid SCHEMBL11684985 | 0.83 | ALDH1A1 (0.86) | ALDH1A1DDX3XCYP1A2HSD17B10RAB9A | |
| SCHEMBL28742509 | 0.83 | HSD17B10 (0.66) | ALDH1A1NQO2HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL8577619 | 0.82 | SMN1; SMN2 (0.70) | ALDH1A1NQO2HSD17B1HSD17B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-0874845-B1 | PYRIDO (2,3-B) PYRAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-6117875-A | Pyrido (2,3-B) pyrazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | ALDH1A1 339/4885NQO2 1132/4885DDX3X 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.